<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36069561</PMID><DateCompleted><Year>2022</Year><Month>10</Month><Day>28</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>03</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">2165-0497</ISSN><JournalIssue CitedMedium="Internet"><Volume>10</Volume><Issue>5</Issue><PubDate><Year>2022</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Microbiology spectrum</Title><ISOAbbreviation>Microbiol Spectr</ISOAbbreviation></Journal><ArticleTitle>B.1.351 SARS-CoV-2 Variant Exhibits Higher Virulence but Less Viral Shedding than That of the Ancestral Strain in Young Nonhuman Primates.</ArticleTitle><Pagination><StartPage>e0226322</StartPage><MedlinePgn>e0226322</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e02263-22</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1128/spectrum.02263-22</ELocationID><Abstract><AbstractText>We investigated the distribution, virulence, and pathogenic characteristics of mutated SARS-CoV-2 to clarify the association between virulence and the viral spreading ability of current and future circulating strains. Chinese rhesus macaques were infected with ancestral SARS-CoV-2 strain GD108 and Beta variant B.1.351 (B.1.351) and assessed for clinical signs, viral distribution, pathological changes, and pulmonary inflammation. We found that GD108 replicated more efficiently in the upper respiratory tract, whereas B.1.351 replicated more efficiently in the lower respiratory tract and lung tissue, implying a reduced viral shedding and spreading ability of B.1.351 compared with that of GD108. Importantly, B.1.351 caused more severe lung injury and dramatically elevated the level of inflammatory cytokines compared with those observed after infection with GD108. Moreover, both B.1.351 and GD108 induced spike-specific T-cell responses at an early stage of infection, with higher levels of interferon gamma (IFN-γ) and tumor necrosis factor alpha (TNF-α) in the B.1.351 group and higher levels of interleukin 17 (IL-17) in the GD108 group, indicating a divergent pattern in the T-cell-mediated inflammatory "cytokine storm." This study provides a basis for exploring the pathogenesis of SARS-CoV-2 variants of concern (VOCs) and establishes an applicable animal model for evaluating the efficacy and safety of vaccines and drugs. <b>IMPORTANCE</b> One of the priorities of the current SARS-CoV-2 vaccine and drug research strategy is to determine the changes in transmission ability, virulence, and pathogenic characteristics of SARS-CoV-2 variants. In addition, nonhuman primates (NHPs) are suitable animal models for the study of the pathogenic characteristics of SARS-CoV-2 and could contribute to the understanding of pathogenicity and transmission mechanisms. As SARS-CoV-2 variants continually emerge and the viral biological characteristics change frequently, the establishment of NHP infection models for different VOCs is urgently needed. In the study, the virulence and tissue distribution of B.1.351 and GD108 were comprehensively studied in NHPs. We concluded that the B.1.351 strain was more virulent but exhibited less viral shedding than the latter. This study provides a basis for determining the pathogenic characteristics of SARS-CoV-2 and establishes an applicable animal model for evaluating the efficacy and safety of vaccines and drugs.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y" EqualContrib="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Yang</LastName><ForeName>Jinghuan</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y" EqualContrib="Y"><LastName>Lu</LastName><ForeName>Shuaiyao</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp; Peking Union Medical College, Kunming People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jialu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Chaoqiang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yu</LastName><ForeName>Wenhai</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp; Peking Union Medical College, Kunming People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Zhongfang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Guangzhou Laboratory, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peng</LastName><ForeName>Xiaozhong</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Institute of Medical Biology, Chinese Academy of Medicine Sciences &amp; Peking Union Medical College, Kunming People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Junzhi</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Miao</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, Institute of Biological Products, National Institutes for Food and Drug Controlgrid.410749.f, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Beijing, People's Republic of China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>09</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Microbiol Spectr</MedlineTA><NlmUniqueID>101634614</NlmUniqueID><ISSNLinking>2165-0497</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D020381">Interleukin-17</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000086663">COVID-19 Vaccines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D014409">Tumor Necrosis Factor-alpha</NameOfSubstance></Chemical><Chemical><RegistryNumber>82115-62-6</RegistryNumber><NameOfSubstance UI="D007371">Interferon-gamma</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Organism" UI="C000711908">SARS-CoV-2 variants</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D020381" MajorTopicYN="N">Interleukin-17</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017201" MajorTopicYN="N">Virus Shedding</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014774" MajorTopicYN="N">Virulence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086663" MajorTopicYN="N">COVID-19 Vaccines</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014409" MajorTopicYN="N">Tumor Necrosis Factor-alpha</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008253" MajorTopicYN="N">Macaca mulatta</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007371" MajorTopicYN="N">Interferon-gamma</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2 variant</Keyword><Keyword MajorTopicYN="N">nonhuman primate</Keyword><Keyword MajorTopicYN="N">viral distribution</Keyword><Keyword MajorTopicYN="N">viral shedding</Keyword><Keyword MajorTopicYN="N">virulence</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>9</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>10</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>9</Month><Day>7</Day><Hour>9</Hour><Minute>4</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>9</Month><Day>7</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36069561</ArticleId><ArticleId IdType="pmc">PMC9603226</ArticleId><ArticleId IdType="doi">10.1128/spectrum.02263-22</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>World Health Organization. WHO coronavirus (COVID-19) dashboard. https://www.who.int/redirect-pages/page/novel-coronavirus-(covid-19)-situation-dashboard. Retrieved 8 April 2022.</Citation></Reference><Reference><Citation>World Health Organization. Tracking SARS-CoV-2 variants. https://www.who.int/en/activities/tracking-SARS-CoV-2-variants/. Retrieved 8 April 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">37184162</ArticleId></ArticleIdList></Reference><Reference><Citation>Bi Z, Hong W, Yang J, Lu S, Peng X. 2021. Animal models for SARS-CoV-2 infection and pathology. MedComm 2:548–568. doi:10.1002/mco2.98.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mco2.98</ArticleId><ArticleId IdType="pmc">PMC8662225</ArticleId><ArticleId IdType="pubmed">34909757</ArticleId></ArticleIdList></Reference><Reference><Citation>Martins M, Fernandes MHV, Joshi LR, Diel DG. 2022. Age-related susceptibility of ferrets to SARS-CoV-2 infection. J Virol 96:e0145521. doi:10.1128/JVI.01455-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01455-21</ArticleId><ArticleId IdType="pmc">PMC8826803</ArticleId><ArticleId IdType="pubmed">34817200</ArticleId></ArticleIdList></Reference><Reference><Citation>Dong W, Mead H, Tian L, Park JG, Garcia JI, Jaramillo S, Barr T, Kollath DS, Coyne VK, Stone NE, Jones A, Zhang J, Li A, Wang LS, Milanes-Yearsley M, Torrelles JB, Martinez-Sobrido L, Keim PS, Barker BM, Caligiuri MA, Yu J. 2022. The K18-human ACE2 transgenic mouse model recapitulates non-severe and severe COVID-19 in response to an infectious dose of the SARS-CoV-2 virus. J Virol 96:e0096421. doi:10.1128/JVI.00964-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00964-21</ArticleId><ArticleId IdType="pmc">PMC8754221</ArticleId><ArticleId IdType="pubmed">34668775</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu S, Zhao Y, Yu W, Yang Y, Gao J, Wang J, Kuang D, Yang M, Yang J, Ma C, Xu J, Qian X, Li H, Zhao S, Li J, Wang H, Long H, Zhou J, Luo F, Ding K, Wu D, Zhang Y, Dong Y, Liu Y, Zheng Y, Lin X, Jiao L, Zheng H, Dai Q, Sun Q, Hu Y, Ke C, Liu H, Peng X. 2020. Comparison of nonhuman primates identified the suitable model for COVID-19. Signal Transduct Target Ther 5:157. doi:10.1038/s41392-020-00269-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00269-6</ArticleId><ArticleId IdType="pmc">PMC7434851</ArticleId><ArticleId IdType="pubmed">32814760</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu P, Qi F, Xu Y, Li F, Liu P, Liu J, Bao L, Deng W, Gao H, Xiang Z, Xiao C, Lv Q, Gong S, Liu J, Song Z, Qu Y, Xue J, Wei Q, Liu M, Wang G, Wang S, Yu H, Liu X, Huang B, Wang W, Zhao L, Wang H, Ye F, Zhou W, Zhen W, Han J, Wu G, Jin Q, Wang J, Tan W, Qin C. 2020. Age-related rhesus macaque models of COVID-19. Animal Model Exp Med 3:93–97. doi:10.1002/ame2.12108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ame2.12108</ArticleId><ArticleId IdType="pmc">PMC7167234</ArticleId><ArticleId IdType="pubmed">32318665</ArticleId></ArticleIdList></Reference><Reference><Citation>Klasse PJ, Nixon DF, Moore JP. 2021. Immunogenicity of clinically relevant SARS-CoV-2 vaccines in nonhuman primates and humans. Sci Adv 7:eabe8065. doi:10.1126/sciadv.abe8065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abe8065</ArticleId><ArticleId IdType="pmc">PMC7978427</ArticleId><ArticleId IdType="pubmed">33608249</ArticleId></ArticleIdList></Reference><Reference><Citation>Chandrashekar A, Liu J, Martinot AJ, McMahan K, Mercado NB, Peter L, Tostanoski LH, Yu J, Maliga Z, Nekorchuk M, Busman-Sahay K, Terry M, Wrijil LM, Ducat S, Martinez DR, Atyeo C, Fischinger S, Burke JS, Slein MD, Pessaint L, Van Ry A, Greenhouse J, Taylor T, Blade K, Cook A, Finneyfrock B, Brown R, Teow E, Velasco J, Zahn R, Wegmann F, Abbink P, Bondzie EA, Dagotto G, Gebre MS, He X, Jacob-Dolan C, Kordana N, Li Z, Lifton MA, Mahrokhian SH, Maxfield LF, Nityanandam R, Nkolola JP, Schmidt AG, Miller AD, Baric RS, Alter G, Sorger PK, Estes JD, et al. . 2020. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 369:812–817. doi:10.1126/science.abc4776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc4776</ArticleId><ArticleId IdType="pmc">PMC7243369</ArticleId><ArticleId IdType="pubmed">32434946</ArticleId></ArticleIdList></Reference><Reference><Citation>Gruber AD, Osterrieder N, Bertzbach LD, Vladimirova D, Greuel S, Ihlow J, Horst D, Trimpert J, Dietert K. 2020. Standardization of reporting criteria for lung pathology in SARS-CoV-2–infected hamsters: what matters? Am J Respir Cell Mol Biol 63:856–859. doi:10.1165/rcmb.2020-0280LE.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2020-0280LE</ArticleId><ArticleId IdType="pmc">PMC7790148</ArticleId><ArticleId IdType="pubmed">32897757</ArticleId></ArticleIdList></Reference><Reference><Citation>Salguero FJ, White AD, Slack GS, Fotheringham SA, Bewley KR, Gooch KE, Longet S, Humphries HE, Watson RJ, Hunter L, Ryan KA, Hall Y, Sibley L, Sarfas C, Allen L, Aram M, Brunt E, Brown P, Buttigieg KR, Cavell BE, Cobb R, Coombes NS, Darby A, Daykin-Pont O, Elmore MJ, Garcia-Dorival I, Gkolfinos K, Godwin KJ, Gouriet J, Halkerston R, Harris DJ, Hender T, Ho CMK, Kennard CL, Knott D, Leung S, Lucas V, Mabbutt A, Morrison AL, Nelson C, Ngabo D, Paterson J, Penn EJ, Pullan S, Taylor I, Tipton T, Thomas S, Tree JA, Turner C, Vamos E, et al. . 2021. Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19. Nat Commun 12:1260. doi:10.1038/s41467-021-21389-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-021-21389-9</ArticleId><ArticleId IdType="pmc">PMC7904795</ArticleId><ArticleId IdType="pubmed">33627662</ArticleId></ArticleIdList></Reference><Reference><Citation>Deng W, Bao L, Liu J, Xiao C, Liu J, Xue J, Lv Q, Qi F, Gao H, Yu P, Xu Y, Qu Y, Li F, Xiang Z, Yu H, Gong S, Liu M, Wang G, Wang S, Song Z, Liu Y, Zhao W, Han Y, Zhao L, Liu X, Wei Q, Qin C. 2020. Primary exposure to SARS-CoV-2 protects against reinfection in rhesus macaques. Science 369:818–823. doi:10.1126/science.abc5343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abc5343</ArticleId><ArticleId IdType="pmc">PMC7402625</ArticleId><ArticleId IdType="pubmed">32616673</ArticleId></ArticleIdList></Reference><Reference><Citation>Shan C, Yao YF, Yang XL, Zhou YW, Gao G, Peng Y, Yang L, Hu X, Xiong J, Jiang RD, Zhang HJ, Gao XX, Peng C, Min J, Chen Y, Si HR, Wu J, Zhou P, Wang YY, Wei HP, Pang W, Hu ZF, Lv LB, Zheng YT, Shi ZL, Yuan ZM. 2020. Infection with novel coronavirus (SARS-CoV-2) causes pneumonia in rhesus macaques. Cell Res 30:670–677. doi:10.1038/s41422-020-0364-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-020-0364-z</ArticleId><ArticleId IdType="pmc">PMC7364749</ArticleId><ArticleId IdType="pubmed">32636454</ArticleId></ArticleIdList></Reference><Reference><Citation>Munster VJ, Feldmann F, Williamson BN, van Doremalen N, Perez-Perez L, Schulz J, Meade-White K, Okumura A, Callison J, Brumbaugh B, Avanzato VA, Rosenke R, Hanley PW, Saturday G, Scott D, Fischer ER, de Wit E. 2020. Respiratory disease in rhesus macaques inoculated with SARS-CoV-2. Nature 585:268–272. doi:10.1038/s41586-020-2324-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2324-7</ArticleId><ArticleId IdType="pmc">PMC7486227</ArticleId><ArticleId IdType="pubmed">32396922</ArticleId></ArticleIdList></Reference><Reference><Citation>Woolsey C, Borisevich V, Prasad AN, Agans KN, Deer DJ, Dobias NS, Heymann JC, Foster SL, Levine CB, Medina L, Melody K, Geisbert JB, Fenton KA, Geisbert TW, Cross RW. 2021. Establishment of an African green monkey model for COVID-19 and protection against re-infection. Nat Immunol 22:86–98. doi:10.1038/s41590-020-00835-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-00835-8</ArticleId><ArticleId IdType="pmc">PMC7790436</ArticleId><ArticleId IdType="pubmed">33235385</ArticleId></ArticleIdList></Reference><Reference><Citation>Munster VJ, Flagg M, Singh M, Yinda CK, Williamson BN, Feldmann F, Pérez-Pérez L, Schulz J, Brumbaugh B, Holbrook MG, Adney DR, Okumura A, Hanley PW, Smith BJ, Lovaglio J, Anzick SL, Martens C, van Doremalen N, Saturday G, de Wit E. 2021. Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B.1.1.7 and B.1.351 in rhesus macaques. Sci Adv doi:10.1126/sciadv.abj3627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.abj3627</ArticleId><ArticleId IdType="pmc">PMC8535829</ArticleId><ArticleId IdType="pubmed">34678071</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Fontela C, Widerspick L, Albrecht RA, Beer M, Carroll MW, de Wit E, Diamond MS, Dowling WE, Funnell SGP, Garcia-Sastre A, Gerhards NM, de Jong R, Munster VJ, Neyts J, Perlman S, Reed DS, Richt JA, Riveros-Balta X, Roy CJ, Salguero FJ, Schotsaert M, Schwartz LM, Seder RA, Segales J, Vasan SS, Henao-Restrepo AM, Barouch DH. 2022. Advances and gaps in SARS-CoV-2 infection models. PLoS Pathog 18:e1010161. doi:10.1371/journal.ppat.1010161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1010161</ArticleId><ArticleId IdType="pmc">PMC8757994</ArticleId><ArticleId IdType="pubmed">35025969</ArticleId></ArticleIdList></Reference><Reference><Citation>Choi JY, Smith DM. 2021. SARS-CoV-2 variants of concern. Yonsei Med J 62:961–968. doi:10.3349/ymj.2021.62.11.961.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2021.62.11.961</ArticleId><ArticleId IdType="pmc">PMC8542474</ArticleId><ArticleId IdType="pubmed">34672129</ArticleId></ArticleIdList></Reference><Reference><Citation>He Q, Mao Q, Peng X, He Z, Lu S, Zhang J, Gao F, Bian L, An C, Yu W, Yang F, Zhou Y, Yang Y, Li Y, Yuan Y, Yan X, Yang J, Wu X, Huang W, Li C, Wang J, Liang Z, Xu M. 2022. Immunogenicity and protective efficacy of a recombinant protein subunit vaccine and an inactivated vaccine against SARS-CoV-2 variants in non-human primates. Signal Transduct Target Ther 7:69. doi:10.1038/s41392-022-00926-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-00926-y</ArticleId><ArticleId IdType="pmc">PMC8892123</ArticleId><ArticleId IdType="pubmed">35241645</ArticleId></ArticleIdList></Reference><Reference><Citation>Cascella M, Rajnik M, Aleem A, Dulebohn SC, Di Napoli R. 2022. Features, evaluation, and treatment of coronavirus (COVID-19). StatPearls Publishing LLC, Treasure Island, FL.</Citation><ArticleIdList><ArticleId IdType="pubmed">32150360</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu T, Qiao J, Zhao L, Wang G, He G, Li K, Tian Y, Gao M, Wang J, Wang H, Dong C. 2006. Acute respiratory distress syndrome induced by avian influenza A (H5N1) virus in mice. Am J Respir Crit Care Med 174:1011–1017. doi:10.1164/rccm.200511-1751OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1164/rccm.200511-1751OC</ArticleId><ArticleId IdType="pubmed">16917113</ArticleId></ArticleIdList></Reference><Reference><Citation>Iwasaki A, Pillai PS. 2014. Innate immunity to influenza virus infection. Nat Rev Immunol 14:315–328. doi:10.1038/nri3665.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3665</ArticleId><ArticleId IdType="pmc">PMC4104278</ArticleId><ArticleId IdType="pubmed">24762827</ArticleId></ArticleIdList></Reference><Reference><Citation>Bai Y, Lian P, Li J, Zhang Z, Qiao J. 2021. The active GLP-1 analogue liraglutide alleviates H9N2 influenza virus-induced acute lung injury in mice. Microb Pathog 150:104645. doi:10.1016/j.micpath.2020.104645.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micpath.2020.104645</ArticleId><ArticleId IdType="pubmed">33285220</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Q, Shi Y, Cai J, Duan Y, Wang R, Zhang H, Ruan Q, Li J, Zhao L, Ping Y, Chen R, Ren L, Fei X, Zhang H, Tang R, Wang X, Luo T, Liu X, Huang X, Liu Z, Ao Q, Ren Y, Xiong J, He Z, Wu H, Fu W, Zhao P, Chen X, Qu G, Wang Y, Wang X, Liu J, Xiang D, Xu S, Zhou X, Li Q, Ma J, Li H, Zhang J, Huang S, Yao X, Zhou Y, Wang C, Zhang D, Wang G, Liu L, Bian XW. 2020. Pathological changes in the lungs and lymphatic organs of 12 COVID-19 autopsy cases. Natl Sci Rev 7:1868–1878. doi:10.1093/nsr/nwaa247.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nsr/nwaa247</ArticleId><ArticleId IdType="pmc">PMC7543449</ArticleId><ArticleId IdType="pubmed">34676085</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun SH, Chen Q, Gu HJ, Yang G, Wang YX, Huang XY, Liu SS, Zhang NN, Li XF, Xiong R, Guo Y, Deng YQ, Huang WJ, Liu Q, Liu QM, Shen YL, Zhou Y, Yang X, Zhao TY, Fan CF, Zhou YS, Qin CF, Wang YC. 2020. A mouse model of SARS-CoV-2 infection and pathogenesis. Cell Host Microbe 28:124–133.e124. doi:10.1016/j.chom.2020.05.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.05.020</ArticleId><ArticleId IdType="pmc">PMC7250783</ArticleId><ArticleId IdType="pubmed">32485164</ArticleId></ArticleIdList></Reference><Reference><Citation>Lupu L, Palmer A, Huber-Lang M. 2020. Inflammation, thrombosis, and destruction: the three-headed cerberus of trauma- and SARS-CoV-2-induced ARDS. Front Immunol 11:584514. doi:10.3389/fimmu.2020.584514.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.584514</ArticleId><ArticleId IdType="pmc">PMC7546394</ArticleId><ArticleId IdType="pubmed">33101314</ArticleId></ArticleIdList></Reference><Reference><Citation>Swenson KE, Swenson ER. 2021. Pathophysiology of acute respiratory distress syndrome and COVID-19 lung injury. Crit Care Clin 37:749–776. doi:10.1016/j.ccc.2021.05.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ccc.2021.05.003</ArticleId><ArticleId IdType="pmc">PMC8162817</ArticleId><ArticleId IdType="pubmed">34548132</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht L, Bishop E, Jay B, Lafoux B, Minoves M, Passaes C. 2021. COVID-19 research: lessons from non-human primate models. Vaccines (Basel) 9:886. doi:10.3390/vaccines9080886.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/vaccines9080886</ArticleId><ArticleId IdType="pmc">PMC8402317</ArticleId><ArticleId IdType="pubmed">34452011</ArticleId></ArticleIdList></Reference><Reference><Citation>Heegaard PMH, Sturek M, Alloosh M, Belsham GJ. 2020. Animal models for COVID-19: more to the picture than ACE2, rodents, ferrets, and non-human primates. A case for porcine respiratory Coronavirus and the obese Ossabaw pig. Front Microbiol 11:573756. doi:10.3389/fmicb.2020.573756.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2020.573756</ArticleId><ArticleId IdType="pmc">PMC7545904</ArticleId><ArticleId IdType="pubmed">33101246</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehaideb SN, Abdullah ML, Abuyassin B, Bouchama A. 2020. Evidence of a wide gap between COVID-19 in humans and animal models: a systematic review. Crit Care 24:594. doi:10.1186/s13054-020-03304-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03304-8</ArticleId><ArticleId IdType="pmc">PMC7537968</ArticleId><ArticleId IdType="pubmed">33023604</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao YD, Ding M, Dong X, Zhang JJ, Kursat Azkur A, Azkur D, Gan H, Sun YL, Fu W, Li W, Liang HL, Cao YY, Yan Q, Cao C, Gao HY, Brüggen MC, van de Veen W, Sokolowska M, Akdis M, Akdis CA. 2021. Risk factors for severe and critically ill COVID-19 patients: a review. Allergy 76:428–455. doi:10.1111/all.14657.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/all.14657</ArticleId><ArticleId IdType="pubmed">33185910</ArticleId></ArticleIdList></Reference><Reference><Citation>Carroll T, Fox D, van Doremalen N, Ball E, Morris MK, Sotomayor-Gonzalez A, Servellita V, Rustagi A, Yinda CK, Fritts L, Port JR, Ma ZM, Holbrook MG, Schulz J, Blish CA, Hanson C, Chiu CY, Munster V, Stanley S, Miller CJ. 2022. The B.1.427/1.429 (Epsilon) SARS-CoV-2 variants are more virulent than ancestral B.1 (614G) in Syrian hamsters. PLoS Pathog 18:e1009914. doi:10.1371/journal.ppat.1009914.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.ppat.1009914</ArticleId><ArticleId IdType="pmc">PMC8865701</ArticleId><ArticleId IdType="pubmed">35143587</ArticleId></ArticleIdList></Reference><Reference><Citation>Habashi NM, Camporota L, Gatto LA, Nieman G. 2021. Functional pathophysiology of SARS-CoV-2-induced acute lung injury and clinical implications. J Appl Physiol (1985) 130:877–891. doi:10.1152/japplphysiol.00742.2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/japplphysiol.00742.2020</ArticleId><ArticleId IdType="pmc">PMC7984238</ArticleId><ArticleId IdType="pubmed">33444117</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekine T, Perez-Potti A, Rivera-Ballesteros O, Stralin K, Gorin JB, Olsson A, Llewellyn-Lacey S, Kamal H, Bogdanovic G, Muschiol S, Wullimann DJ, Kammann T, Emgard J, Parrot T, Folkesson E, Karolinska C-SG, Rooyackers O, Eriksson LI, Henter JI, Sonnerborg A, Allander T, Albert J, Nielsen M, Klingstrom J, Gredmark-Russ S, Bjorkstrom NK, Sandberg JK, Price DA, Ljunggren HG, Aleman S, Buggert M, Karolinska COVID-19 Study Group . 2020. Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell 183:158–16.e114. doi:10.1016/j.cell.2020.08.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.08.017</ArticleId><ArticleId IdType="pmc">PMC7427556</ArticleId><ArticleId IdType="pubmed">32979941</ArticleId></ArticleIdList></Reference><Reference><Citation>Toor SM, Saleh R, Sasidharan Nair V, Taha RZ, Elkord E. 2021. T-cell responses and therapies against SARS-CoV-2 infection. Immunology 162:30–43. doi:10.1111/imm.13262.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13262</ArticleId><ArticleId IdType="pmc">PMC7730020</ArticleId><ArticleId IdType="pubmed">32935333</ArticleId></ArticleIdList></Reference><Reference><Citation>Xin Z, Zheng A, Li D, Zhang R, Sun H, Wang Q, Gao GF, Han P, Dai L. 2021. Neutralisation of ZF2001-elicited antisera to SARS-CoV-2 variants. The Lancet Microbe 2:e494. doi:10.1016/S2666-5247(21)00217-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2666-5247(21)00217-2</ArticleId><ArticleId IdType="pmc">PMC8378832</ArticleId><ArticleId IdType="pubmed">34458880</ArticleId></ArticleIdList></Reference><Reference><Citation>Halfmann PJ, Iida S, Iwatsuki-Horimoto K, Maemura T, Kiso M, Scheaffer SM, Darling TL, Joshi A, Loeber S, Singh G, Foster SL, Ying B, Case JB, Chong Z, Whitener B, Moliva J, Floyd K, Ujie M, Nakajima N, Ito M, Wright R, Uraki R, Warang P, Gagne M, Li R, Sakai-Tagawa Y, Liu Y, Larson D, Osorio JE, Hernandez-Ortiz JP, Henry AR, Ciuoderis K, Florek KR, Patel M, Odle A, Wong L-YR, Bateman AC, Wang Z, Edara V-V, Chong Z, Franks J, Jeevan T, Fabrizio T, DeBeauchamp J, Kercher L, Seiler P, Gonzalez-Reiche AS, Sordillo EM, Chang LA, van Bakel H, et al. . 2022. SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters. Nature 603:687–692. doi:10.1038/s41586-022-04441-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-022-04441-6</ArticleId><ArticleId IdType="pmc">PMC8942849</ArticleId><ArticleId IdType="pubmed">35062015</ArticleId></ArticleIdList></Reference><Reference><Citation>Berkhout B, Herrera-Carrillo E, Gallagher T. 2022. SARS-CoV-2 evolution: on the sudden appearance of the Omicron variant. J Virol 96:e00090-22. doi:10.1128/jvi.00090-22.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.00090-22</ArticleId><ArticleId IdType="pmc">PMC9006888</ArticleId><ArticleId IdType="pubmed">35293771</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung C, Kmiec D, Koepke L, Zech F, Jacob T, Sparrer KMJ, Kirchhoff F, Aguilar HC. 2022. Omicron: what makes the latest SARS-CoV-2 variant of concern so concerning? J Virol 96:e02077-21. doi:10.1128/jvi.02077-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.02077-21</ArticleId><ArticleId IdType="pmc">PMC8941872</ArticleId><ArticleId IdType="pubmed">35225672</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiao L, Li H, Xu J, Yang M, Ma C, Li J, Zhao S, Wang H, Yang Y, Yu W, Wang J, Yang J, Long H, Gao J, Ding K, Wu D, Kuang D, Zhao Y, Liu J, Lu S, Liu H, Peng X. 2021. The gastrointestinal tract is an alternative route for SARS-CoV-2 infection in a nonhuman primate model. Gastroenterology 160:1647–1661. doi:10.1053/j.gastro.2020.12.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1053/j.gastro.2020.12.001</ArticleId><ArticleId IdType="pmc">PMC7725054</ArticleId><ArticleId IdType="pubmed">33307034</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>